NCT05160766View on ClinicalTrials.gov

Assessing Immune Response of Different COVID-19 Vaccines in Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

September 13, 2023

Conditions
Prevention of COVID-19
Interventions
BIOLOGICAL

Comirnaty (BTN162b2)

Single booster shot (3rd dose in Part A and 4th dose in Part B)

BIOLOGICAL

Spikevax (mRNA-1273)

Single booster shot (3rd dose in Part A and 4th dose in Part B)

Trial Locations (9)

5021

Helse Bergen HF, Haukeland University Hospital, Bergen

14004

Reina Sofia University Hospital, Córdoba

20014

Biodonostia Health Research Institute, San Sebastián

28046

La Paz University Hospital, Madrid

30625

Hannover Medical School Hospital, Hanover

50931

University Hospital Cologne, Cologne

60590

University Hospital Frankfurt, Frankfurt

08661

Vilnius University Hospital Santaros Klinikos, Vilnius

08916

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
collaborator

VACCELERATE

UNKNOWN

collaborator

European Commission

OTHER

lead

Oliver Cornely, MD

OTHER

NCT05160766 - Assessing Immune Response of Different COVID-19 Vaccines in Older Adults | Biotech Hunter | Biotech Hunter